As part of the commitment to strengthening local vaccine manufacturing, a team from Kenya BioVax Institute Limited (KBI) toured Tasa Pharma’s facilities to explore strategic collaborations in research, technology transfer, and production. The visit provided an opportunity to assess Tasa Pharma’s cutting-edge manufacturing capabilities and diverse product portfolio, including essential vaccines and biologics tailored for the African market.
Discussions centered on leveraging local expertise, enhancing regulatory compliance, and scaling up regional production to support Africa’s goal of vaccine self-sufficiency. By fostering partnerships with industry leaders like Tasa Pharma, KBI aims to drive innovation and ensure sustainable access to high-quality, locally manufactured vaccines.
